BBOT
What one share of BridgeBio Oncology Therapeutics holds
Pharmaceutical Preparations
BBOT is a clinical-stage biotechnology company with the mission of transforming the lives of patients with cancers driven by RAS and PI3Kα, the two most frequently mutated oncogenes. Aberrant RAS signaling drives uncontrolled tumor growth in some of the deadliest cancers, including lung, breast, pancreas and colon cancer.
BridgeBio Oncology Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.67 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$3.06 |
| Cash and investments | $4.30 |
| Book value | $4.03 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2025 | — | −$4.30 | $0.02 | −$3.68 | — | $5.14 |